Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Standards of care"
Filter
Filter
Article category
Keywords
Publication year
Authors
Review
Drug/Regimen
Article image
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Päivi Maria Paldánius
Diabetes Metab J. 2020;44(6):785-801.   Published online September 15, 2020
DOI: https://doi.org/10.4093/dmj.2020.0179
  • 7,899 View
  • 304 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and associated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with sequential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. However, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declining β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-implemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients worldwide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical implementation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evidence.

Citations

Citations to this article as recorded by  
  • A retrospective cohort study of a community-based primary care program’s effects on pharmacotherapy quality in low-income Peruvians with type 2 diabetes and hypertension
    John E. Deaver, Gabriela M. Uchuya, Wayne R. Cohen, Janet A. Foote, Harry H. X. Wang
    PLOS Global Public Health.2024; 4(8): e0003512.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP